Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04064840
Other study ID # UW 18-393
Secondary ID 06171626
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 1, 2019
Est. completion date December 30, 2024

Study information

Verified date August 2023
Source The University of Hong Kong
Contact Ernest HY Ng, MD
Phone 852-28553400
Email nghye@hku.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.


Description:

Trial design: A randomised, double-blinded and placebo controlled trial will be performed in IVF cycles and another randomised, double-blinded and placebo controlled trial will be performed in FET cycles. Treatment of subjects: IVF Women being scheduled for IVF at Department of Obstetrics & Gynaecology of Kwong Wah Hospital and Queen Mary Hospital will be assessed for eligibility. Eligible women will be recruited for the study and each woman will only be included in the study. Informed written consent will be obtained after counseling. All techniques of IVF including ovarian stimulation, harvesting of oocytes, insemination with specially prepared sperm and embryo culture in the laboratory will be according to local protocols. Women will receive ovarian stimulation using antagonist protocol. Ultrasound scanning will be arranged on day 2-3 of menses for the antral follicle counts and to exclude the presence of ovarian cyst. Oestradiol and progesterone concentration will be checked and if they are basal, ovarian stimulation with gonadotropin injections will be given. GnRH antagonist will be started on day 6 of ovarian stimulation. Regular ultrasound monitoring will be performed to monitor the growth of follicles. Adjustment of the gonadotropin dosage is corresponding to the number and size of follicles. Randomization When three follicles reach 18 mm in diameter, recruited women will be randomized according to a computer-generated randomization list prepared by a designated research nurse into one of the following: (1) the dual trigger: recombinant hCG 0.25mg and decapeptyl 0.2mg subcutaneously and (2) the hCG trigger: recombinant hCG 0.25mg subcutaneously and normal saline. Transvaginal ultrasound-guided egg retrieval will be scheduled 36 hours after the dual or hCG trigger. Intracytoplasmic sperm injection will be performed if necessary, depending on the semen quality of the husbands. A maximum of 2 embryos or blastocysts will be replaced 2 days or 5 days after egg retrieval according to the standard protocol under transabdominal ultrasound guidance. Two days after egg retrieval, each woman will receive vaginal progesterone (Endometrin 100mg bd) for two weeks for the luteal phase support. FET Women being scheduled for FET will be assessed for eligibility. Eligible women will be recruited for the study and each woman will only be included in the study with one FET cycle. Informed written consent will be obtained. Women with regular ovulatory cycles will undergo the standard procedures of blood taking to identify the day of luteinizing hormone (LH) surge, which is defined as an elevation of the LH to 2 times the level of the average of the previous 3 days and the absolute level of the LH surge is greater than 20 IU/L. Transvaginal ultrasound will be done to measure the endometrial thickness on the day after the LH surge. A maximum of two early cleavage embryos or two blastocysts will be transferred 3 days or 6 days after the LH surge respectively. Randomization On the day of FET, recruited women will be randomized into one of the following two groups: (1) decapeptyl 0.1 mg subcutaneously and (2) normal saline as control group according to a computer-generated randomization list prepared by a designated research nurse. The rest of the embryo transfer procedure will be the same as our usual practice. Blinding The women and the physicians will not know the group allocation. Only the research nurse will know the group allocation, but they will not be involved in the patient care. Follow-up and data collection A urine pregnancy test is performed 18 days after the dual or hCG trigger in IVF cycles or the LH surge in FET cycles. If the pregnancy test is positive, transvaginal ultrasound will be performed 2 weeks later to locate the pregnancy and foetal viability. Subsequent management will be the same as other women with early pregnancy. They will be referred for antenatal care when the pregnancy is on-going at 8-10 weeks. Follow-up Written consent regarding retrieval of pregnancy and delivery data from both public and private sectors will be sought from the patient at the time of study. The obstetric outcomes will be traced from the electric patient record system if the patients deliver in Hospital Authority hospitals. A pre-formatted letter with replying address available will be given to the patient at the end of the study period and is to be filled by the private obstetrician and returned to us after delivery. If no reply letter is received 2-3 months after the expected date of confinement of the patient, a letter including patient's authorization will be sent to the corresponding private obstetrician to retrieve the information of the pregnancy outcomes. The outcome of the pregnancy (delivery, miscarriage), number of babies born, birth weights and obstetrics complications will be recorded.


Recruitment information / eligibility

Status Recruiting
Enrollment 784
Est. completion date December 30, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 42 Years
Eligibility IVF Inclusion criteria: - Women aged <43 years at the time of IVF treatment Exclusion criteria: - Preimplantation genetic diagnosis treatment - Use of donor oocytes or donor embryos - Hydrosalpinx shown on pelvic scanning and not surgically treated - Women at risk of OHSS FET Inclusion criteria: - Women aged <43 years at the time of IVF treatment - Replacing early cleavage embryos or blastocysts after thawing - FET in natural cycles Exclusion criteria: - Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient - Preimplantation genetic diagnosis treatment - Use of donor oocytes or donor embryos - Hydrosalpinx shown on pelvic scanning and not surgically treated

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IVF: Decapeptyl and hCG
When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
FET: Decapeptyl
On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
IVF: hCG and normal saline
When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
FET: Normal Saline
On the day of FET, normal saline will be injected subcutaneously.

Locations

Country Name City State
China Department of Obstetrics and Gynaecology Hong Kong Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Live birth rate delivery after 22 weeks after 22 weeks
Secondary Pregnancy positive urine pregnancy test 18 days after the dual or hCG trigger in IVF cycles or the LH surge in FET cycles
Secondary Clinical pregnancy presence of intrauterine gestational sac on ultrasound 6 weeks
Secondary Biochemical pregnancy positive urine pregnancy test not followed by clinical pregnancy before 6 weeks
Secondary Ongoing pregnancy viable pregnancy beyond gestation 8 weeks 8 weeks
Secondary Implantation rate number of gestational sacs per embryo transferred 1 day
Secondary Adverse events Ovarian hyperstimulation syndrome 8 weeks
Secondary Neonatal outcome Birth weight of babies 40 weeks
See also
  Status Clinical Trial Phase
Completed NCT03569787 - Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire
Completed NCT03105453 - The Microbiome in Subfertility and Assisted Reproductive Technologies (ART)
Terminated NCT02180256 - Effect of Endometrial Scratching on Assisted Reproduction Outcomes: a Randomized Controlled Trial N/A
Terminated NCT02197832 - A RCT on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing FET Cycles N/A
Completed NCT00971152 - Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle Phase 3
Completed NCT01569945 - Hormonal Stimulation in IUI Treatment: Is Clomifen Combined With Ethinyl Estradiol Better, Worse or Equal to Menopur N/A
Recruiting NCT02561793 - DHEA Versus Placebo in Women With Poor Ovarian Response Phase 3
Terminated NCT02570386 - Clinical Effectiveness of Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer N/A
Completed NCT02197208 - A RCT Comparing Spontaneous Natural Cycles and Human Chorionic Gonadotrophin-induced Natural Cycles in FET N/A
Completed NCT01961336 - Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF Phase 3
Completed NCT02487940 - Assessment of Intralipid Efficacy in Women With Unexplained Recurrent Implantation Failure Phase 4
Completed NCT01385618 - Gene-polymorphisms Relating to Human Subfertility N/A
Completed NCT00985062 - Mild Versus Conventional Ovarian Stimulation Treatment for In Vitro Fertilization N/A
Recruiting NCT04538560 - Preimplantation Genetic Testing for Aneuploidy of Polar Bodies N/A
Completed NCT02748278 - Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women in IVF Treatment
Completed NCT02044445 - Is the IVF Outcome Dependent on the Time Interval Between hCG Administration and Oocyte Retrieval? N/A
Completed NCT02863614 - Analgesia for Endometrial Scratching N/A
Completed NCT02151006 - Does Dehydro Epiandrosterone (DHEA) Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response? Phase 3
Completed NCT02154958 - Role of Follicular Output Rate in the Prediction of in Vitro Fertilization and Intracytoplasmic Sperm Injection in Women With Unexplained Infertility N/A
Completed NCT01067664 - Prognostic Value of Progesterone for In Vitro Fertilization (IVF) Outcome N/A